RxDoctor Payments Data

Francis Nardella, MD

Rheumatology · Meridian, IDNPI 1780735571

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,284 of the $3,434 with a category attached, or 66.5%. 15 manufacturers reported payments, led by Boehringer Ingelheim at 34.7% of the total. Reporting peaked in 2020 at $1,091 and has fallen 97.6% since, to $26 in 2024.

$3,434in general payments, 2019–2025

Across 136 payments — averaging $25.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$1K
  • Amgen$709
  • Johnson & Johnson$479
  • Genentech USA, Inc.$222
  • Mallinckrodt Hospital Products Inc.$204
  • AbbVie$132
  • plus $497 from 9 others

What the payments were for

  • Consulting fees$1,05031%
  • Food & beverage$2,28467%
  • Education$1003%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,434 in reported general payments places this provider in the 70th percentile of 28 rheumatology providers in Idaho.

See all rheumatology providers in Idaho

Medicare billing

Part B allowed, 2024
$12,691
Medicare patients
53
Services billed
104

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib30$191,610
KevzaraSarilumab14$60,328
Mycophenolate Mofetil11$2,964
Leflunomide17$1,155
Prednisone83$1,060
Hydroxychloroquine Sulfate26$960
MethotrexateMethotrexate Sodium21$385
Sulfasalazine15$274
Allopurinol16$113

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$132$191,61030 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 28 rheumatology providers in Idaho.

Other rheumatology in Meridian

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →